Table 4.

Prognostic significance of molecular and clinical factors identified by multivariate Cox regression analysis

VariablesUnivariate analysis
Multivariate analysis*
Unadjusted RR (95% CI)PAdjusted RR (95% CI)P
p53 immunostaining
    Negative1.001.00
    Positive2.021 (1.13-3.616)0.0181.331 (0.703-2.522)0.38
TP53 mutations
    Wild-type1.001.00
    Mutated1.051 (0.596-1.851)0.8640.648 (0.333-1.26)0.201
p53 immunohistochemistry + mutation
    Normal1.001.00
    Wild-type, overexpression2.548 (1.188-5.465)0.0161.598 (0.662-3.856)0.297
    Mutated, no expression1.922 (0.87-4.246)0.884 (0.336-2.325)
    Mutated, overexpression1.284 (0.524-3.145)0.82 (0.299-2.246)
p53 altered
    Normal1.001.00
    Altered1.901 (0.985-3.667)0.0451.107 (0.498-2.461)0.804
Arg72Pro SNP
    Arg/Arg1.001.00
    Arg/Pro0.747 (0.386-1.446)1.693 (0.769-3.728)
    Pro/Pro1.371 (0.588-3.200)0.4126.452 (1.072-6.452)0.035
Histology
    Serous1.001.00
    Nonserous1.938 (1.011-3.717)1.449 (0.672-3.124)
    Undifferentiated3.679 (1.284-10.54)0.0321.590 (0.419-6.033)0.496
Ascites
    No1.001.00
    Yes3.015 (1.27-7.161)0.011.681 (0.695-1.681)0.249
Relapse
    No1.001.00
    Yes22.34 (3.072-162.54)0.00211.769 (1.374-100.77)0.024
Residual disease
    None1.001.00
    Any6.556 (2.976-14.444)<0.0015.255 (1.648-29.588)0.008
FIGO stage
    I1.001.00
    II1.462 (0.449-4.764)1.403 (0.378-5.210)
    III3.175 (1.505-6.697)1.542 (0.523-4.541)
    IV9.922 (2.932-33.577)<0.0016.983 (1.648-29.588)0.008
  • Abbreviations: RR, relative risk; 95% CI, 95% confidence interval.

  • * Adjusted to FIGO stage and residual disease.